Cantor Fitzgerald Forecasts Rezolute FY2025 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Rezolute in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($0.97) per share for the year. The consensus estimate for Rezolute’s current full-year earnings is ($0.99) per share.

Rezolute (NASDAQ:RZLT) last released its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.13.

Other analysts also recently issued research reports about the company. Wedbush reiterated an “outperform” rating and issued a $112.00 price objective on shares of Rezolute in a research report on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Rezolute in a research report on Friday, November 8th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $24.13.

Rezolute Stock Down 2.2 %

Shares of RZLT opened at $4.81 on Thursday. The company has a 50-day simple moving average of $4.89 and a 200-day simple moving average of $4.85. Rezolute has a 52 week low of $0.92 and a 52 week high of $6.19.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in RZLT. Dimensional Fund Advisors LP acquired a new position in shares of Rezolute in the second quarter valued at approximately $255,000. XTX Topco Ltd grew its holdings in shares of Rezolute by 205.8% during the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares in the last quarter. Marshall Wace LLP bought a new stake in Rezolute during the second quarter worth about $4,503,000. Cubist Systematic Strategies LLC lifted its position in Rezolute by 366.0% during the second quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock worth $233,000 after purchasing an additional 42,597 shares during the period. Finally, Affinity Asset Advisors LLC raised its position in shares of Rezolute by 15.6% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock valued at $7,955,000 after buying an additional 250,000 shares in the last quarter. Institutional investors own 82.97% of the company’s stock.

Insider Transactions at Rezolute

In other Rezolute news, CFO Daron Evans bought 9,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $4.60 per share, for a total transaction of $41,400.00. Following the transaction, the chief financial officer now owns 140,900 shares of the company’s stock, valued at approximately $648,140. The trade was a 6.82 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 18.39% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.